Metrics to compare | ACTI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACTIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.2x | −2.5x | −0.6x | |
PEG Ratio | −0.06 | −0.07 | 0.00 | |
Price/Book | 2.8x | 2.8x | 2.6x | |
Price / LTM Sales | - | 15.1x | 3.2x | |
Upside (Analyst Target) | - | 118.2% | 48.1% | |
Fair Value Upside | Unlock | 48.4% | 5.8% | Unlock |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.